Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
KPTI 
Karyopharm Therapeutics Inc (KPTI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: KPTI (1-star) is a SELL. SELL since 4 days. Simulated Profits (-1.61%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $23.07
1 Year Target Price $23.07
| 2 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -49.39% | Avg. Invested days 28 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 48.73M USD | Price to earnings Ratio - | 1Y Target Price 23.07 |
Price to earnings Ratio - | 1Y Target Price 23.07 | ||
Volume (30-day avg) 6 | Beta 0.34 | 52 Weeks Range 3.51 - 16.95 | Updated Date 10/13/2025 |
52 Weeks Range 3.51 - 16.95 | Updated Date 10/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -14.84 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -90.02% | Operating Margin (TTM) -64.3% |
Management Effectiveness
Return on Assets (TTM) -45.16% | Return on Equity (TTM) -891.05% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 193463338 | Price to Sales(TTM) 0.35 |
Enterprise Value 193463338 | Price to Sales(TTM) 0.35 | ||
Enterprise Value to Revenue 1.41 | Enterprise Value to EBITDA -1.85 | Shares Outstanding 8671278 | Shares Floating 7933959 |
Shares Outstanding 8671278 | Shares Floating 7933959 | ||
Percent Insiders 6.16 | Percent Institutions 51.06 |
Upturn AI SWOT
Karyopharm Therapeutics Inc
Company Overview
History and Background
Karyopharm Therapeutics Inc. was founded in 2008. It is a commercial-stage pharmaceutical company pioneering novel therapies for cancer and other diseases. The company is focused on discovering, developing, and commercializing first-in-class drugs directed against nuclear transport and related targets.
Core Business Areas
- Oncology: Develops and commercializes therapies for hematologic malignancies and solid tumors, with a focus on XPOVIO (selinexor).
Leadership and Structure
Dr. Richard Paulson is the President and Chief Executive Officer. The company has a typical biopharmaceutical organizational structure, with departments focused on research and development, clinical operations, commercial operations, and corporate functions.
Top Products and Market Share
Key Offerings
- XPOVIO (selinexor): XPOVIO is an oral Selective Inhibitor of Nuclear Export (SINE) compound. It is approved for multiple myeloma, diffuse large B-cell lymphoma (DLBCL), and endometrial cancer. Revenue from XPOVIO was approximately $105 million in 2023. Competitors depend on the indication but include Bristol Myers Squibb (multiple myeloma), Novartis (DLBCL), and GSK (multiple myeloma).
Market Dynamics
Industry Overview
The oncology therapeutics market is large and competitive, with ongoing innovation and high demand for new therapies. Targeted therapies and immunotherapies are key trends.
Positioning
Karyopharm is positioned as a company focused on developing novel SINE compounds for cancer treatment. Its competitive advantage lies in its first-in-class technology and its approved drug, XPOVIO.
Total Addressable Market (TAM)
The global oncology market is projected to reach hundreds of billions of dollars. Karyopharm is targeting specific segments within this market, with XPOVIO addressing unmet needs in multiple myeloma, DLBCL, and endometrial cancer. Karyopharm is positioned to capture a portion of the relevant TAM.
Upturn SWOT Analysis
Strengths
- First-in-class SINE technology
- Approved product (XPOVIO) with multiple indications
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Sole reliance on XPOVIO for revenue
- Financial losses and dependence on funding
- Competition from established players
- Concerns about side effects of XPOVIO
Opportunities
- Expansion of XPOVIO to new indications
- Development of next-generation SINE compounds
- Partnerships and collaborations
- Growing demand for targeted cancer therapies
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from biosimilars or generics
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- BMS
- NVS
- GSK
- MRK
- JNJ
Competitive Landscape
Karyopharm faces intense competition from established pharmaceutical companies with larger resources and broader product portfolios. Its competitive advantage lies in its novel SINE technology, but it needs to demonstrate the efficacy and safety of its drugs to gain market share.
Growth Trajectory and Initiatives
Historical Growth: Karyopharm has experienced revenue growth driven by XPOVIO sales. However, it has also faced challenges related to clinical trial results and regulatory approvals.
Future Projections: Future growth is expected to be driven by further expansion of XPOVIO to new indications and the development of its pipeline. Analyst estimates vary depending on the success of clinical trials and regulatory approvals.
Recent Initiatives: Recent initiatives include pursuing additional indications for XPOVIO, advancing its pipeline of next-generation SINE compounds, and seeking partnerships to expand its reach.
Summary
Karyopharm is a high-risk, high-reward biopharmaceutical company with a novel technology. While XPOVIO sales are growing, the company is still losing money. Future success depends on expanding XPOVIO's indications and developing its pipeline, but regulatory and competitive challenges loom large.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Karyopharm Therapeutics Inc. SEC Filings
- Company Website
- Analyst Reports
- Market Research Reports
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. Investment decisions should be made based on your own due diligence and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Karyopharm Therapeutics Inc
Exchange NASDAQ | Headquaters Newton, MA, United States | ||
IPO Launch date 2013-11-06 | President, CEO & Director Mr. Richard A. Paulson M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 279 | Website https://www.karyopharm.com |
Full time employees 279 | Website https://www.karyopharm.com | ||
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.